Last reviewed · How we verify
Bellus Health Inc. - a GSK company — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| 3APS | 3APS | phase 3 | P2X3 receptor antagonist | P2X3 | Respiratory | |
| BLU-5937 | BLU-5937 | phase 3 | P2X3 receptor antagonist | P2X3 | Pain Management / Neurology | |
| Tramiprosate (3APS) | Tramiprosate (3APS) | phase 3 | Amyloid-beta aggregation inhibitor | Amyloid-beta (Aβ) | Neurology |
Therapeutic area mix
- Neurology · 1
- Pain Management / Neurology · 1
- Respiratory · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Grünenthal GmbH · 1 shared drug class
- Mundipharma Research GmbH & Co KG · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Bellus Health Inc. - a GSK company:
- Bellus Health Inc. - a GSK company pipeline updates — RSS
- Bellus Health Inc. - a GSK company pipeline updates — Atom
- Bellus Health Inc. - a GSK company pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Bellus Health Inc. - a GSK company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bellus-health-inc-a-gsk-company. Accessed 2026-05-17.